- KR₩128bn
- KR₩271bn
- KR₩160bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 1.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.33% | ||
| Return on Equity | -17.87% | ||
| Operating Margin | -12.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 137,184.19 | 124,599.96 | 142,238.42 | 156,042.33 | 160,352.78 | n/a | n/a | 5.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +56.6 | -48.14 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CKD Bio Corp. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. It also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The Company distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.
Directors
- Joeng Jin Lee CEO (52)
- Saeng Gyu Seo OTH (55)
- Hak Yeon Hwang OTH (59)
- Hae Mun Lee OTH (57)
- Gwang Seop Gil NID (65)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 12th, 2001
- Public Since
- December 11th, 2001
- No. of Shareholders
- 26,338
- No. of Employees
- 349
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 5,485,959
- Address
- Chongkundang Bldg., SEOUL, 03742
- Web
- https://www.ckdbio.com/
- Phone
- +82 221940555
- Auditors
- Daejoo Accounting Corp.
Upcoming Events for 063160
Q2 2024 CKD Bio Corp Earnings Release
Similar to 063160
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
Daewon Pharmaceutical Co
Korea Exchange - KSE
FAQ
What is the CKD Bio share price?
As of Today at 19:05 UTC, shares in CKD Bio are trading at KR₩23,350. This share price information is delayed by 15 minutes.
How has the CKD Bio share price performed this year?
Shares in CKD Bio last closed at KR₩23,350 and the price had moved by -12.34% over the past 365 days. In terms of relative price strength the CKD Bio share price has underperformed the FTSE Developed Asia Pacific Index by -8.5% over the past year.
What are the analyst and broker recommendations for CKD Bio?
The overall consensus recommendation for CKD Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the CKD Bio dividend yield?
CKD Bio does not currently pay a dividend.
Does CKD Bio pay a dividend?
CKD Bio does not currently pay a dividend.
When does CKD Bio next pay dividends?
CKD Bio does not currently pay a dividend.
How do I buy CKD Bio shares?
To buy shares in CKD Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CKD Bio?
As of the previous close price of KR₩23,350, shares in CKD Bio had a market capitalisation of KR₩128bn.
Where are CKD Bio shares listed?
Here are the trading details for CKD Bio:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 063160
What kind of share is CKD Bio?
Based on an overall assessment of its quality, value and momentum CKD Bio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CKD Bio share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the CKD Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CKD Bio. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +10.26%.
As of the last closing price of KR₩23,350, shares in CKD Bio were trading +2.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CKD Bio PE Ratio?
The CKD Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩23,350.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CKD Bio?
CKD Bio's management team is headed by:
- Joeng Jin Lee - CEO
- Saeng Gyu Seo - OTH
- Hak Yeon Hwang - OTH
- Hae Mun Lee - OTH
- Gwang Seop Gil - NID